SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2057Sanofi "dropped" Aflibercept ophthalmic indication (and kept oncology)Miljenko Zuanic-3/8/2017
2056Very strange indeed, they had a peek at REGN data, was not impressed and then laFelix B-3/7/2017
2055What is this SHIT? 12 min for primary Fourier presentation??? wwwext.amgen.com Miljenko Zuanic-3/6/2017
2054<Seems like AZN approached SNY, not the other way around.> I am not sure Miljenko Zuanic-3/3/2017
2053<We know that they spent a loot (I mean, A LOOT!), but cutting on genomics anBiotech Jim-3/3/2017
2052I think the second one. Have no idea WHY REGN partner IO with Sanofi? We know tMiljenko Zuanic-3/3/2017
2051Seems like AZN approached SNY, not the other way around.DewDiligence_on_SI-3/3/2017
2050Longer half life in the MEDI Ab and the MEDI group experience? Or trying to divBiotech Jim-3/3/2017
2049On watch.. [graphic]hollyhunter-3/3/2017
2048Sanofi Antibody Collaboration: They did not want REGN222, but they did pay extMiljenko Zuanic-3/3/2017
2047biopharmadive.com By this, LeTrait facility would be OK at Oct-2016, pre Sur-apMiljenko Zuanic13/2/2017
2046REGN-Adverum extended collaboration on XLRS: sec.govMiljenko Zuanic-3/2/2017
2045REGN contra act: regeneron.com A LONG-TERM GLOBAL COMMITMENT IOPS has been manuMiljenko Zuanic-2/27/2017
2044Beginning of the end between Sanofi and REGN, or "end of beginning"?: Miljenko Zuanic-2/27/2017
2043Anyone with idea what is 'wrong" with REGN at this point of "SanofMiljenko Zuanic-2/23/2017
2042Damage to Praluent is already done and will increase in coming months. But, therMiljenko Zuanic-2/9/2017
2041While overturning is certainly good news, I can't imagine given the uncertaiFelix B-2/9/2017
2040That was time-point when injunction was to start, which was overturned yesterdayMiljenko Zuanic-2/9/2017
2039You said in earlier thread appeal decision was 45 days from Jan 5 or was that inFelix B-2/9/2017
2038For now Praluent stay on market. finance.yahoo.comMiljenko Zuanic-2/8/2017
2037Ok—we're on the same wavelength.DewDiligence_on_SI-2/3/2017
2036I did not say "impressive", I said "only" positive. I do agrMiljenko Zuanic-2/3/2017
203522% RRR (if that's what is turns out to be) is a meh result, IMO, insofar asDewDiligence_on_SI-2/3/2017
2034Dos REGN222 (anti-RSV Ab) have future? fiercebiotech.comMiljenko Zuanic-2/3/2017
2033It is 50 : 50, or less. )-:Miljenko Zuanic-2/3/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News